137 related articles for article (PubMed ID: 23452608)
21. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
Lieberthal W; Levine JS
Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
[TBL] [Abstract][Full Text] [Related]
22. mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse.
Neasta J; Barak S; Hamida SB; Ron D
J Neurochem; 2014 Jul; 130(2):172-84. PubMed ID: 24666346
[TBL] [Abstract][Full Text] [Related]
23. Requirement for lysosomal localization of mTOR for its activation differs between leucine and other amino acids.
Averous J; Lambert-Langlais S; Carraro V; Gourbeyre O; Parry L; B'Chir W; Muranishi Y; Jousse C; Bruhat A; Maurin AC; Proud CG; Fafournoux P
Cell Signal; 2014 Sep; 26(9):1918-27. PubMed ID: 24793303
[TBL] [Abstract][Full Text] [Related]
24. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
Bracho-Valdés I; Moreno-Alvarez P; Valencia-Martínez I; Robles-Molina E; Chávez-Vargas L; Vázquez-Prado J
IUBMB Life; 2011 Oct; 63(10):896-914. PubMed ID: 21905202
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin treatment improves neuron viability in an in vitro model of stroke.
Fletcher L; Evans TM; Watts LT; Jimenez DF; Digicaylioglu M
PLoS One; 2013; 8(7):e68281. PubMed ID: 23861877
[TBL] [Abstract][Full Text] [Related]
26. Targeting mTOR Signaling Can Prevent the Progression of FSGS.
Zschiedrich S; Bork T; Liang W; Wanner N; Eulenbruch K; Munder S; Hartleben B; Kretz O; Gerber S; Simons M; Viau A; Burtin M; Wei C; Reiser J; Herbach N; Rastaldi MP; Cohen CD; Tharaux PL; Terzi F; Walz G; Gödel M; Huber TB
J Am Soc Nephrol; 2017 Jul; 28(7):2144-2157. PubMed ID: 28270414
[TBL] [Abstract][Full Text] [Related]
27. Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components.
Saxena A; Sampson JR
Semin Cell Dev Biol; 2014 Dec; 36():140-6. PubMed ID: 25263008
[TBL] [Abstract][Full Text] [Related]
28. Influence of mTOR in energy and metabolic homeostasis.
Haissaguerre M; Saucisse N; Cota D
Mol Cell Endocrinol; 2014 Nov; 397(1-2):67-77. PubMed ID: 25109278
[TBL] [Abstract][Full Text] [Related]
29. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
30. Role of mTOR Inhibitors in Kidney Disease.
Kajiwara M; Masuda S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338360
[TBL] [Abstract][Full Text] [Related]
31. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.
Yin Y; Hua H; Li M; Liu S; Kong Q; Shao T; Wang J; Luo Y; Wang Q; Luo T; Jiang Y
Cell Res; 2016 Jan; 26(1):46-65. PubMed ID: 26584640
[TBL] [Abstract][Full Text] [Related]
32. Chronic activation of mTOR complex 1 by branched chain amino acids and organ hypertrophy.
Neishabouri SH; Hutson SM; Davoodi J
Amino Acids; 2015 Jun; 47(6):1167-82. PubMed ID: 25721400
[TBL] [Abstract][Full Text] [Related]
33. Stoichiometry and assembly of mTOR complexes revealed by single-molecule pulldown.
Jain A; Arauz E; Aggarwal V; Ikon N; Chen J; Ha T
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):17833-8. PubMed ID: 25453101
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite Formation In Vitro.
Leitmeyer K; Glutz A; Radojevic V; Setz C; Huerzeler N; Bumann H; Bodmer D; Brand Y
Biomed Res Int; 2015; 2015():925890. PubMed ID: 25918725
[TBL] [Abstract][Full Text] [Related]
35. An mTORC1-Mdm2-Drosha axis for miRNA biogenesis in response to glucose- and amino acid-deprivation.
Ye P; Liu Y; Chen C; Tang F; Wu Q; Wang X; Liu CG; Liu X; Liu R; Liu Y; Zheng P
Mol Cell; 2015 Feb; 57(4):708-720. PubMed ID: 25639470
[TBL] [Abstract][Full Text] [Related]
36. Hypothalamic mTOR: the rookie energy sensor.
Martínez de Morentin PB; Martinez-Sanchez N; Roa J; Ferno J; Nogueiras R; Tena-Sempere M; Dieguez C; Lopez M
Curr Mol Med; 2014 Jan; 14(1):3-21. PubMed ID: 24236459
[TBL] [Abstract][Full Text] [Related]
37. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
38. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
39. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.
Schreiber KH; Ortiz D; Academia EC; Anies AC; Liao CY; Kennedy BK
Aging Cell; 2015 Apr; 14(2):265-73. PubMed ID: 25652038
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
